Estrogen administration attenuates immobilization-induced skeletal muscle atrophy in male rats.
We tested the hypothesis that estrogen administration would retard immobilization-induced muscle atrophy in adult male rats. The rats were injected for 24 days with either estrogen (40 microg/kg(-1), beta-estradiol 3-benzoate in olive oil vehicle), or vehicle alone. At day 14 of estrogen treatment, the hindlimb muscles of one leg were immobilized in plantar flexion position by the use of a plaster cast. Following 10 days of immobilzation, the atrophic and the contralateral soleus muscles were both removed and analyzed to determine the level of muscle atrophy along with the measurement of the protein levels of Cu-Zn-superoxide dismutase (Cu-Zn-SOD), heat shock protein 72 (HSP72), and selected proteases. Compared to placebo animals, estrogen treatment significantly reduced (-35%) muscle atrophy. Further, estrogen significantly abridged the expression of the calcium-activated protease, calpain, in the atrophied hindlimb muscle. In contrast, estrogen treatment did not alter the protein levels of HSP72 in the immobilized soleus muscle. These results support the postulate that estrogen attenuates the rate of disuse muscle atrophy, partly because of reductions in immobilization-induced calcium-activated protease levels.
Sugiura
Takao
T
Department of Exercise and Health Sciences, Yamaguchi University, Yamaguchi, 753-8513 Japan. takahito@yamaguchi-u.ac.jp
Ito
Naoko
N
Goto
Katsumasa
K
Naito
Hisashi
H
Yoshioka
Toshitada
T
Powers
Scott K
SK
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002154:Calpain / Q000378:metabolism; D004967:Estrogens / Q000494:pharmacology*; D050884:HSP72 Heat-Shock Proteins / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D009133:Muscular Atrophy / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D018384:Oxidative Stress / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012149:Restraint, Physical / Q000009:adverse effects; D013482:Superoxide Dismutase / Q000378:metabolism
D000975:Antioxidants; D004967:Estrogens; D050884:HSP72 Heat-Shock Proteins; D013482:Superoxide Dismutase; D002154:Calpain